WO2003049694A3 - Methodes therapeutiques de traitement d'un lymphome non hodgkinien - Google Patents

Methodes therapeutiques de traitement d'un lymphome non hodgkinien Download PDF

Info

Publication number
WO2003049694A3
WO2003049694A3 PCT/US2002/039253 US0239253W WO03049694A3 WO 2003049694 A3 WO2003049694 A3 WO 2003049694A3 US 0239253 W US0239253 W US 0239253W WO 03049694 A3 WO03049694 A3 WO 03049694A3
Authority
WO
WIPO (PCT)
Prior art keywords
lymphoma
methods
antibody
therapeutic
hodgkin
Prior art date
Application number
PCT/US2002/039253
Other languages
English (en)
Other versions
WO2003049694A2 (fr
Inventor
Maurice J Wolin
Sandra Milan
Deborah Hurst
Original Assignee
Chiron Corp
Maurice J Wolin
Sandra Milan
Deborah Hurst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/293,664 external-priority patent/US20030185796A1/en
Application filed by Chiron Corp, Maurice J Wolin, Sandra Milan, Deborah Hurst filed Critical Chiron Corp
Priority to AU2002362098A priority Critical patent/AU2002362098A1/en
Priority to JP2003550745A priority patent/JP2005538034A/ja
Priority to EP02797231A priority patent/EP1463524A4/fr
Priority to CA002469045A priority patent/CA2469045A1/fr
Publication of WO2003049694A2 publication Critical patent/WO2003049694A2/fr
Publication of WO2003049694A3 publication Critical patent/WO2003049694A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des méthodes de traitement d'un être humain atteint d'un lymphome à l'aide d'une combinaison d'interleukine-2 et d'au moins un anticorps anti-CD20. Ces agents thérapeutiques sont administrés dans deux compositions pharmaceutiques séparées, une contenant l'IL-2, l'autre contenant au moins un anticorps anti-CD20, selon un régime de dosage. L'administration conjointe de ces deux agents thérapeutiques augmente l'efficacité d'un quelconque des deux agents utilisé individuellement, permettant d'obtenir une réponse thérapeutique positive améliorée par rapport à celle observée avec un quelconque des deux agents utilisé individuellement. Les effets thérapeutiques de ces agents peuvent être obtenus par utilisation de dosages inférieurs d'IL-2, réduisant ainsi la toxicité d'une administration d'IL-2 prolongée et le potentiel d'échappement tumoral.
PCT/US2002/039253 2001-12-07 2002-12-06 Methodes therapeutiques de traitement d'un lymphome non hodgkinien WO2003049694A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2002362098A AU2002362098A1 (en) 2001-12-07 2002-12-06 Methods of therapy for non-hodgkin's lymphoma
JP2003550745A JP2005538034A (ja) 2001-12-07 2002-12-06 非ホジキンリンパ腫の治療方法
EP02797231A EP1463524A4 (fr) 2001-12-07 2002-12-06 Methodes therapeutiques de traitement d'un lymphome non hodgkinien
CA002469045A CA2469045A1 (fr) 2001-12-07 2002-12-06 Methodes therapeutiques de traitement d'un lymphome non hodgkinien

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1796801A 2001-12-07 2001-12-07
US10/017,968 2001-12-07
US10/293,664 US20030185796A1 (en) 2000-03-24 2002-11-12 Methods of therapy for non-hodgkin's lymphoma
US10/293,664 2002-11-12

Publications (2)

Publication Number Publication Date
WO2003049694A2 WO2003049694A2 (fr) 2003-06-19
WO2003049694A3 true WO2003049694A3 (fr) 2003-11-06

Family

ID=26690566

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/039253 WO2003049694A2 (fr) 2001-12-07 2002-12-06 Methodes therapeutiques de traitement d'un lymphome non hodgkinien

Country Status (5)

Country Link
EP (1) EP1463524A4 (fr)
JP (1) JP2005538034A (fr)
AU (1) AU2002362098A1 (fr)
CA (1) CA2469045A1 (fr)
WO (1) WO2003049694A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101969980A (zh) * 2008-01-17 2011-02-09 菲洛根股份公司 抗-EDb纤连蛋白抗体-IL-2融合蛋白与结合至B细胞、B祖细胞和/或它们的癌性对应物的分子的组合物

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227217B1 (en) 2002-12-16 2010-11-29 Genentech Inc Immunoglobulin variants and uses thereof
KR20060027801A (ko) 2003-06-05 2006-03-28 제넨테크, 인크. Ｂ 세포 장애에 대한 조합 요법
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
AU2004308452A1 (en) * 2003-12-22 2005-07-14 Novartis Vaccines And Diagnostics, Inc. Use of Fc receptor polymorphisms as diagnostics for treatment strategies for immune-response disorders
US20050265966A1 (en) 2004-05-20 2005-12-01 Kindsvogel Wayne R Methods of treating cancer using IL-21 and monoclonal antibody therapy
MY194883A (en) 2004-06-04 2022-12-21 Genentech Inc Method for treating multiple sclerosis
US20060251617A1 (en) * 2005-02-15 2006-11-09 Chiron Corporation Methods for treating lymphomas
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
KR101643514B1 (ko) 2007-07-09 2016-07-27 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
EP2200631A1 (fr) 2007-10-16 2010-06-30 Zymogenetics, Inc. Combinaison d'agents d'inhibition de blys et d'agents anti-cd 20 pour le traitement d'une maladie auto-immune
EP2077281A1 (fr) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anticorps anti-CD20 ou fragments correspondants pour le traitement de syndrome de fatigue chronique
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
DK2464725T3 (da) 2009-08-11 2020-06-02 Hoffmann La Roche Fremstilling af proteiner i glutaminfrie celledyrkningsmedier
WO2011100403A1 (fr) 2010-02-10 2011-08-18 Immunogen, Inc Anticorps anti-cd20 et utilisations de ceux-ci
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
CA2997801A1 (fr) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anticorps de recepteur de la transferrine humaine/anti-humaine cd20 bispecifique et leurs procedes d'utilisation
CN115369086B (zh) * 2022-02-22 2023-05-12 北京景达生物科技有限公司 一种nk细胞扩大培养的培养方案

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020009427A1 (en) * 2000-03-24 2002-01-24 Wolin Maurice J. Methods of therapy for non-hodgkin's lymphoma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020009427A1 (en) * 2000-03-24 2002-01-24 Wolin Maurice J. Methods of therapy for non-hodgkin's lymphoma

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1463524A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101969980A (zh) * 2008-01-17 2011-02-09 菲洛根股份公司 抗-EDb纤连蛋白抗体-IL-2融合蛋白与结合至B细胞、B祖细胞和/或它们的癌性对应物的分子的组合物

Also Published As

Publication number Publication date
EP1463524A2 (fr) 2004-10-06
CA2469045A1 (fr) 2003-06-19
EP1463524A4 (fr) 2005-02-09
JP2005538034A (ja) 2005-12-15
WO2003049694A2 (fr) 2003-06-19
AU2002362098A8 (en) 2003-06-23
AU2002362098A1 (en) 2003-06-23

Similar Documents

Publication Publication Date Title
WO2003049694A3 (fr) Methodes therapeutiques de traitement d'un lymphome non hodgkinien
NZ217483A (en) Composition for delivery of hydrophobic drugs
BRPI0414876A (pt) compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos
CR6458A (es) Composiciones de valdecoxib
EP1478371A4 (fr) Methodes et produits permettant d'ameliorer des reponses immunitaires a l'aide de compose d'imidazoquinoline
HUP0102521A2 (hu) Sztilbénszármazékot és platina koordinációs vegyületet tartalmazó daganatellenes szer
ATE102838T1 (de) Zusammensetzungen zur behandlung von neoplasia mit gehalt an neoplasmushemmendem mittel und nebenwirkungen reduzierendem schutzmittel.
HK1030157A1 (en) Use of consensus interferon and compositions comprising consensus interferon.
WO2004045593A3 (fr) Polytherapie anticancereuse au moyen d'un compose anticancereux active par gst et d'un autre traitement anticancereux
DE69434121D1 (de) Pharmazeutische zusammensetzung zur immunstimulierenden therapie
DE60036915D1 (de) Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
IL121272A (en) Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
WO2001074365A3 (fr) Posologie efficace de galantamine reduisant les effets secondaires
GB0018322D0 (en) Pharmaceutical compositions
KR930003913A (ko) 덱스트로메토르판의 진해효과를 증진시키기 위한 방법 및 약제학적 조성물
EP0272393A3 (fr) Mélange pharmaceutique
EP1374873B8 (fr) Utilisation de la n-acetyl-d-glucosamine dans la preparation de compositions pharmaceutiques utilisees dans la suppression des effets secondaires causes par la radiotherapie et la chimiotherapie
WO2002076393A3 (fr) Agents antiangionenes, antitumoraux, et chimiopreventifs
EP1384487A4 (fr) Medicaments contenant un anticorps genetiquement modifie dirige contre un ganglioside gd3
MXPA04002099A (es) Composiciones medicinales para neuropatia diabetica.
KR870010871A (ko) 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법
WO2003061571A3 (fr) Therapie combinee avec il-2 et des anticorps anti-her2 pour les cancers caracterises par la surexpression de la proteine receptrice her2
RU2002129097A (ru) Комбинированные терапии с использованием активности, повреждающей сосуды

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003550745

Country of ref document: JP

Ref document number: 2469045

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002797231

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002797231

Country of ref document: EP